Percent cases averted through vaccination in a scenario with a 95% effective vaccine conferring lifelong immunity, without changes to screening or sexual risk behavior. Vaccine-preventable HPV infections (types 16, 18, 6, and 11) constitute 77% of cervical cancers, 39% of cervical intraepithelial neoplasias grade 1 (CIN1), 60% of CIN2/3, and 90% of genital warts cases at baseline (0% vaccination). Solid lines reflect female-only vaccination (red, CIN1; orange, CIN2/3; green, cancer; blue, warts); dashed lines reflect vaccination of both genders. The transmission dynamics of low-risk HPV types differs from that of the high-risk types, hence the impact of vaccination on warts produces a qualitatively different trajectory from vaccination's impact on cancer and precancerous lesions. Cases averted plateaus due to other strains not covered by the vaccine.